Financial

BioCardia Signs Exclusive Development Agreement With AstraZeneca

SAN CARLOS, Calif., July 25, 2019 (GLOBE NEWSWIRE) — BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced it has signed an extension to a 2017 development agreement with AstraZeneca [NYSE:AZN] for BioCardia’s Helix™ biotherapeutic delivery catheter system. Under the terms of the initial pre-clinical […]

AliveCor Appoints Priya Abani as Chief Executive Officer; Elevates Vinod Khosla to Chairman of the Board

MOUNTAIN VIEW, Calif., July 24, 2019 /PRNewswire/ — AliveCor, the leader in FDA-cleared consumer electrocardiogram technology, today announced the appointment of Priya Abani as Chief Executive Officer. Abani comes to the company with decades of experience creating scale in digital platform technologies. Most recently, Abani was the General Manager for Devices and Enablement at […]

U.S. FDA Accepts Correvio’s Resubmitted New Drug Application For Brinavess (vernakalant)

VANCOUVER, July 25, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for Brinavess™ (vernakalant hydrochloride, IV), an antiarrhythmic drug for the rapid conversion […]

NeuroPace Announces Michael Favet as CEO

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–NeuroPace, Inc., a Silicon Valley-based medical technology company, today announced the appointment of Michael Favet as Chief Executive Officer. Frank Fischer, after 20 years serving as CEO, continues with NeuroPace as Chairman of the Board of Directors. Mr. Favet has served on the NeuroPace board since 2016, […]

HeartHero Closes Series A Round, Secures Funding for FDA Submission

DENVER–(BUSINESS WIRE)–HeartHero announces the closing of its oversubscribed Series A funding round. This funding secures a pathway for Elliot, an industry disruptive Automated External Defibrillator (AED), to be submitted for FDA Class III approval and CE mark. This round provides resources for high-volume manufacturing and launches HeartHero’s unique go-to-market strategy for […]

Julie Stephenson Joins BioSig as Senior Director of Clinical Affairs

Westport, CT, July 24, 2019 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing technology platform designed to address an unmet need for the electrophysiology (EP) marketplace, today announced that Ms. Julie Stephenson, BSN, MBA joined the Company as Senior Director of Clinical Affairs. […]

Boston Scientific Announces Results For Second Quarter 2019

MARLBOROUGH, Mass., July 24, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated sales of $2.631 billion during the second quarter of 2019. This represents growth of 5.6 percent on a reported basis, 8.0 percent on an operational1 basis and 6.3 percent on an organic2 basis, all compared to the prior year period. The company reported […]

Ablacon Announces Closing of a $10 Million Venture Debt Facility and $2 Million Equity Investment from Western Technology Investment; Josef Koblish and Melissa Kong to Join the Company

MENLO PARK, Calif., July 23, 2019 /PRNewswire/ — Ablacon Inc. announced today that it has entered into a $10 millionventure debt facility with Western Technology Investment (WTI). The debt is accompanied by a $2 million equity investment in the Company. This financing will help fund Ablacon’s first multicenter randomized clinical trial for Ablamap, an advanced mapping […]

Edwards Lifesciences Reports Second Quarter Results

IRVINE, Calif., July 23, 2019 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended June 30, 2019. Second Quarter and Recent Highlights Sales grew 15% to $1.1 billion; underlying1 sales grew 14% TAVR sales grew 16%; underlying […]